Connect
MJA
MJA

NSAIDs and stroke risk

David J Blacker
Med J Aust 2011; 195 (9): 488. || doi: 10.5694/mja11.11185
Published online: 7 November 2011

Recent studies build a strong case to suggest that there is a clear risk

Clearly, stroke prevention is preferable to the currently available treatments, particularly for haemorrhagic stroke. The burden of stroke is substantial, so all strategies to reduce risk must be considered. The traditional risk factors, especially hypertension, are well recognised, but there is also increasing interest in identifying and modulating novel risks1 and precipitant causes. In this issue of the Journal, an important article by Caughey and colleagues2 adds to the growing literature concerning the risk of stroke related to the use of non-steroidal anti-inflammatory drugs (NSAIDs), particularly those with selective cyclooxygenase (COX)-2 inhibition. If the use of these agents is a clear and substantial risk, then avoiding such medications, particularly in high-risk patients, may be an important preventive strategy. But is the risk clear and substantial, or are other factors involved? Is there a potential for abandoning useful medications and also creating undue anxiety for patients currently using them to treat painful chronic conditions?

  • David J Blacker1,2

  • 1 Sir Charles Gairdner Hospital, Perth, WA.
  • 2 University of Western Australia, Perth, WA.


Competing interests:

I have received support for travel and accommodation at meetings from Boehringer Ingelheim and Sanofi–Synthelabo. I have also received advisory board fees from Novo Nordisk and per-patient payments to my institution from Servier for a clinical trial.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.